

# Toshitsugu Sugimoto

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7481100/publications.pdf>

Version: 2024-02-01

155  
papers

7,636  
citations

47006

47  
h-index

58581

82  
g-index

161  
all docs

161  
docs citations

161  
times ranked

7132  
citing authors

#	ARTICLE	IF	CITATIONS
1	Higher Serum Uric Acid is a Risk Factor of Reduced Muscle Mass in Men with Type 2 Diabetes Mellitus. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2021, 129, 50-55.	1.2	13
2	Efficacy of once-weekly and twice-weekly injections of teriparatide by patient characteristics: A post hoc analysis of the TWICE study. <i>Osteoporosis and Sarcopenia</i> , 2021, 7, 11-16.	1.9	1
3	Which Is a Better Skeletal Muscle Mass Index for the Evaluation of Physical Abilities: The Present Height or Maximum Height?. <i>Internal Medicine</i> , 2021, 60, 1191-1196.	0.7	3
4	A randomized, controlled trial of once-weekly teriparatide injection versus alendronate in patients at high risk of osteoporotic fracture: primary results of the Japanese Osteoporosis Intervention Trial-05. <i>Osteoporosis International</i> , 2021, 32, 2301-2311.	3.1	24
5	Acute Phase Reactions After Intravenous Infusion of Zoledronic Acid in Japanese Patients with Osteoporosis: Sub-analyses of the Phase III ZONE Study. <i>Calcified Tissue International</i> , 2021, 109, 666-674.	3.1	9
6	Relationship Between Changes in Serum Levels of Intact Parathyroid Hormone and Sclerostin After a Single Dose of Zoledronic Acid: Results of a Phase 1 Pharmacokinetic Study. <i>Calcified Tissue International</i> , 2021, , 1.	3.1	1
7	Higher Serum Uric Acid is a Risk Factor of Vertebral Fractures in Postmenopausal Women with Type 2 Diabetes Mellitus. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2020, 128, 66-71.	1.2	4
8	Safety Profiles, Pharmacokinetics, and Changes in Bone Turnover Markers After Twice-Weekly Subcutaneous Administration of Teriparatide in Healthy Japanese Postmenopausal Women: A Single-Blind Randomized Study. <i>Clinical Pharmacology in Drug Development</i> , 2020, 9, 87-96.	1.6	4
9	Phase II/III, randomized, double-blind, parallel-group study of monthly delayed-release versus daily immediate-release risedronate tablets in Japanese patients with involutional osteoporosis. <i>Journal of Bone and Mineral Metabolism</i> , 2020, 38, 86-98.	2.7	1
10	Papillary thyroid carcinoma is a risk factor for severe osteoporosis. <i>Journal of Bone and Mineral Metabolism</i> , 2020, 38, 264-270.	2.7	9
11	Design of a randomized trial of teriparatide followed by alendronate: Japanese Osteoporosis Intervention Trial-05 (JOINT-05). <i>Journal of Bone and Mineral Metabolism</i> , 2020, 38, 412-417.	2.7	8
12	A pregnant woman with an autonomously functioning thyroid nodule: a case report. <i>Gynecological Endocrinology</i> , 2020, 36, 1140-1143.	1.7	3
13	Efficacy of denosumab co-administered with vitamin D and Ca by baseline vitamin D status. <i>Journal of Bone and Mineral Metabolism</i> , 2020, 38, 848-858.	2.7	7
14	Randomized head-to-head comparison of minodronic acid and raloxifene for fracture incidence in postmenopausal Japanese women: the Japanese Osteoporosis Intervention Trial (JOINT)-04. <i>Current Medical Research and Opinion</i> , 2020, 36, 1847-1859.	1.9	3
15	Relationship Between Bone Mineral Density and Risk of Vertebral Fractures with Denosumab Treatment in Japanese Postmenopausal Women and Men with Osteoporosis. <i>Calcified Tissue International</i> , 2020, 107, 559-566.	3.1	4
16	Executive summary of clinical practice guide on fracture risk in lifestyle diseases. <i>Journal of Bone and Mineral Metabolism</i> , 2020, 38, 746-758.	2.7	8
17	Association between elcatonin use and cancer risk in Japan: A follow-up study after a randomized, double-blind, placebo-controlled study of once-weekly elcatonin in primary postmenopausal osteoporosis. <i>Osteoporosis and Sarcopenia</i> , 2020, 6, 15-19.	1.9	1
18	Modulators of Fam210a and Roles of Fam210a in the Function of Myoblasts. <i>Calcified Tissue International</i> , 2020, 106, 533-540.	3.1	7

#	ARTICLE	IF	CITATIONS
19	A randomized, double-blind, placebo-controlled study of once weekly elcatonin in primary postmenopausal osteoporosis. <i>Current Medical Research and Opinion</i> , 2019, 35, 447-454.	1.9	5
20	Study design of multi-center, open-label randomized controlled, head-to-head trial comparing minodronic acid and raloxifene: Japanese Osteoporosis Intervention Trial (JOINT)-04. <i>Journal of Bone and Mineral Metabolism</i> , 2019, 37, 491-495.	2.7	7
21	Study of twice-weekly injections of Teriparatide by comparing efficacy with once-weekly injections in osteoporosis patients: the TWICE study. <i>Osteoporosis International</i> , 2019, 30, 2321-2331.	3.1	17
22	Bazedoxifene Ameliorates Homocysteine-Induced Apoptosis via NADPH Oxidase-Interleukin 1 $\beta$ and 6 Pathway in Osteocyte-like Cells. <i>Calcified Tissue International</i> , 2019, 105, 446-457.	3.1	5
23	Phloretin Suppresses Bone Morphogenetic Protein-2-Induced Osteoblastogenesis and Mineralization via Inhibition of Phosphatidylinositol 3-kinases/Akt Pathway. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2481.	4.1	14
24	Low skeletal muscle mass is associated with the risk of all-cause mortality in patients with type 2 diabetes mellitus. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2019, 10, 204201881984297.	3.2	27
25	Incidence of osteonecrosis of the jaw in Japanese osteoporosis patients taking minodronic acid. <i>Journal of Bone and Mineral Metabolism</i> , 2019, 37, 886-892.	2.7	14
26	A scoring assessment tool for the risk of vertebral fractures in patients with type 2 diabetes mellitus. <i>Bone</i> , 2019, 122, 38-44.	2.9	4
27	Insulin-Like Growth Factor-I Protects Against the Detrimental Effects of Advanced Glycation End Products and High Glucose in Myoblastic C2C12 Cells. <i>Calcified Tissue International</i> , 2019, 105, 89-96.	3.1	15
28	Osteoporosis and vertebral fracture are associated with deterioration of activities of daily living and quality of life in patients with type 2 diabetes mellitus. <i>Journal of Bone and Mineral Metabolism</i> , 2019, 37, 503-511.	2.7	23
29	Overweight and underweight are risk factors for vertebral fractures in patients with type 2 diabetes mellitus. <i>Journal of Bone and Mineral Metabolism</i> , 2019, 37, 703-710.	2.7	11
30	FAM210A is a novel determinant of bone and muscle structure and strength. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E3759-E3768.	7.1	49
31	Osteoblast AMP-Activated Protein Kinase Regulates Postnatal Skeletal Development in Male Mice. <i>Endocrinology</i> , 2018, 159, 597-608.	2.8	17
32	Diabetes and Osteoporosis. , 2018, , 127-139.		0
33	Association of Bone Mineral Density, Bone Turnover Markers, and Vertebral Fractures with All-Cause Mortality in Type 2 Diabetes Mellitus. <i>Calcified Tissue International</i> , 2018, 102, 1-13.	3.1	41
34	Glucose uptake inhibition decreases expressions of receptor activator of nuclear factor-kappa B ligand (RANKL) and osteocalcin in osteocytic MLO-Y4-A2 cells. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2018, 314, E115-E123.	3.5	18
35	Albuminuria Increases All-Cause Mortality in Japanese Patients with Type 2 Diabetes Mellitus. <i>Journal of Clinical Medicine</i> , 2018, 7, 234.	2.4	4
36	Diabetes Mellitus-induced Bone Fragility. <i>Internal Medicine</i> , 2018, 57, 2773-2785.	0.7	37

#	ARTICLE	IF	CITATIONS
37	The Association Between Osteocalcin and Chronic Inflammation in Patients with Type 2 Diabetes Mellitus. <i>Calcified Tissue International</i> , 2018, 103, 599-605.	3.1	13
38	Osteoblast AMP-activated protein kinase regulates glucose metabolism and bone mass in adult mice. <i>Biochemical and Biophysical Research Communications</i> , 2018, 503, 1955-1961.	2.1	8
39	Visceral fat accumulation is associated with increased plasma sphingosine-1-phosphate levels in type 2 diabetes mellitus. <i>Diabetes Research and Clinical Practice</i> , 2018, 143, 146-150.	2.8	16
40	Phloretin Promotes Adipogenesis via Mitogen-Activated Protein Kinase Pathways in Mouse Marrow Stromal ST2 Cells. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1772.	4.1	21
41	Assessment using serum insulin-like growth factor-I and bone mineral density is useful for detecting prevalent vertebral fractures in patients with type 2 diabetes mellitus. <i>Osteoporosis International</i> , 2018, 29, 2527-2535.	3.1	18
42	Advanced Glycation End Product 3 (AGE3) Increases Apoptosis and the Expression of Sclerostin by Stimulating TGF- $\beta$ 2 Expression and Secretion in Osteocyte-Like MLO-Y4-A2 Cells. <i>Calcified Tissue International</i> , 2017, 100, 402-411.	3.1	25
43	24-Month Open-Label Teriparatide Once-Weekly Efficacy Research Trial Examining Bone Mineral Density in Subjects with Primary Osteoporosis and High Fracture Risk. <i>Advances in Therapy</i> , 2017, 34, 1727-1740.	2.9	16
44	Bazedoxifene Ameliorates Homocysteine-Induced Apoptosis and Accumulation of Advanced Glycation End Products by Reducing Oxidative Stress in MC3T3-E1 Cells. <i>Calcified Tissue International</i> , 2017, 100, 286-297.	3.1	25
45	Association of osteoglycin and FAM5C with bone turnover markers, bone mineral density, and vertebral fractures in postmenopausal women with type 2 diabetes mellitus. <i>Bone</i> , 2017, 95, 5-10.	2.9	8
46	Long-term efficacy and safety of vildagliptin add-on therapy in type 2 diabetes mellitus with insulin treatment. <i>Diabetes Research and Clinical Practice</i> , 2017, 123, 9-17.	2.8	14
47	Assessment criteria for vitamin D deficiency/insufficiency in Japan: proposal by an expert panel supported by the Research Program of Intractable Diseases, Ministry of Health, Labour and Welfare, Japan, the Japanese Society for Bone and Mineral Research and the Japan Endocrine Society [Opinion]. <i>Journal of Bone and Mineral Metabolism</i> , 2017, 35, 1-5.	2.7	82
48	Decreased Serum Insulin-like Growth Factor-I is a Risk Factor for Non-vertebral Fractures in Diabetic Postmenopausal Women. <i>Internal Medicine</i> , 2017, 56, 269-273.	0.7	17
49	Advanced Glycation End-Products Induce Apoptosis of Vascular Smooth Muscle Cells: A Mechanism for Vascular Calcification. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1567.	4.1	39
50	Elevated Serum Pentosidine and Decreased Serum IGF-I Levels are Associated with Loss of Muscle Mass in Postmenopausal Women with Type 2 Diabetes Mellitus. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2016, 124, 163-166.	1.2	25
51	Visceral fat obesity increases serum DPP-4 levels in men with type 2 diabetes mellitus. <i>Diabetes Research and Clinical Practice</i> , 2016, 116, 1-6.	2.8	15
52	Advanced Glycation End Products, Diabetes, and Bone Strength. <i>Current Osteoporosis Reports</i> , 2016, 14, 320-326.	3.6	144
53	Simvastatin rescues homocysteine-induced apoptosis of osteocytic MLO-Y4 cells by decreasing the expressions of NADPH oxidase 1 and 2. <i>Endocrine Journal</i> , 2016, 63, 389-395.	1.6	15
54	Decreased serum insulin-like growth factor-I level is associated with the increased mortality in type 2 diabetes mellitus. <i>Endocrine Journal</i> , 2016, 63, 811-818.	1.6	9

#	ARTICLE	IF	CITATIONS
55	Reduced muscle mass and accumulation of visceral fat are independently associated with increased arterial stiffness in postmenopausal women with type 2 diabetes mellitus. <i>Diabetes Research and Clinical Practice</i> , 2016, 122, 141-147.	2.8	25
56	Treatment responses with once-weekly teriparatide therapy for osteoporosis. <i>Osteoporosis International</i> , 2016, 27, 3057-3062.	3.1	14
57	Serum dipeptidyl peptidase-4 is associated with multiple vertebral fractures in type 2 diabetes mellitus. <i>Clinical Endocrinology</i> , 2016, 84, 332-337.	2.4	9
58	Activation of AMP-activated protein kinase decreases receptor activator of NF- $\kappa$ B ligand expression and increases sclerostin expression by inhibiting the mevalonate pathway in osteocytic MLO-Y4 cells. <i>Biochemical and Biophysical Research Communications</i> , 2016, 469, 791-796.	2.1	18
59	Renal Phosphate Reabsorption is Correlated with the Increase in Lumbar Bone Mineral Density in Patients Receiving Once-Weekly Teriparatide. <i>Calcified Tissue International</i> , 2016, 98, 186-192.	3.1	4
60	Efficacy and Safety of Risedronate in Osteoporosis Subjects with Comorbid Diabetes, Hypertension, and/or Dyslipidemia: A Post Hoc Analysis of Phase III Trials Conducted in Japan. <i>Calcified Tissue International</i> , 2016, 98, 114-122.	3.1	32
61	Fracture Risk in Diabetes. , 2016, , 27-42.		0
62		0.0	0
63	Effects of high glucose and advanced glycation end products on the expressions of sclerostin and RANKL as well as apoptosis in osteocyte-like MLO-Y4-A2 cells. <i>Biochemical and Biophysical Research Communications</i> , 2015, 461, 193-199.	2.1	145
64	Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT). <i>Osteoporosis International</i> , 2015, 26, 765-774.	3.1	49
65	Activation of AMP-activated protein kinase protects against homocysteine-induced apoptosis of osteocytic MLO-Y4 cells by regulating the expressions of NADPH oxidase 1 (Nox1) and Nox2. <i>Bone</i> , 2015, 77, 135-141.	2.9	35
66	Reduction in Endogenous Insulin Secretion is a Risk Factor of Sarcopenia in Men with Type 2 Diabetes Mellitus. <i>Calcified Tissue International</i> , 2015, 97, 385-390.	3.1	44
67	<i>Clinical Trials Express:</i> Fracture Risk Reduction With Denosumab in Japanese Postmenopausal Women and Men With Osteoporosis: Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT). <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 2599-2607.	3.6	138
68	Author's Response to Letter to the Editor. <i>Current Medical Research and Opinion</i> , 2014, 30, 1627-1628.	1.9	0
69	Changes in bone mineral density, bone turnover markers, and vertebral fracture risk reduction with once weekly teriparatide. <i>Current Medical Research and Opinion</i> , 2014, 30, 931-936.	1.9	17
70	The effects of once-weekly teriparatide on hip geometry assessed by hip structural analysis in postmenopausal osteoporotic women with high fracture risk. <i>Bone</i> , 2014, 64, 75-81.	2.9	12
71	Involvement of the Osteoinductive Factors, Tmem119 and BMP-2, and the ER Stress Response PERK-eIF2 $\gamma$ -ATF4 Pathway in the Commitment of Myoblastic into Osteoblastic Cells. <i>Calcified Tissue International</i> , 2014, 94, 454-464.	3.1	44
72	Once-weekly teriparatide reduces the risk of vertebral fracture in patients with various fracture risks: subgroup analysis of the Teriparatide Once-Weekly Efficacy Research (TOWER) trial. <i>Journal of Bone and Mineral Metabolism</i> , 2014, 32, 441-446.	2.7	27

#	ARTICLE	IF	CITATIONS
73	The effects of once-weekly teriparatide on hip structure and biomechanical properties assessed by CT. <i>Osteoporosis International</i> , 2014, 25, 1163-1172.	3.1	29
74	Profile of changes in bone turnover markers during once-weekly teriparatide administration for 24 weeks in postmenopausal women with osteoporosis. <i>Osteoporosis International</i> , 2014, 25, 1173-1180.	3.1	48
75	Advanced Glycation End Product 3 (AGE3) Suppresses the Mineralization of Mouse Stromal ST2 Cells and Human Mesenchymal Stem Cells by Increasing TGF- $\beta$ 2 Expression and Secretion. <i>Endocrinology</i> , 2014, 155, 2402-2410.	2.8	56
76	Once-weekly teriparatide administration for 24 weeks in postmenopausal women with osteoporosis: reply to T. Kawada. <i>Osteoporosis International</i> , 2014, 25, 2323-2324.	3.1	0
77	Active vitamin D possesses beneficial effects on the interaction between muscle and bone. <i>Biochemical and Biophysical Research Communications</i> , 2014, 450, 482-487.	2.1	62
78	New simulation model for bone formation markers in osteoporosis patients treated with once-weekly teriparatide. <i>Bone Research</i> , 2014, 2, 14043.	11.4	8
79	Serum osteocalcin levels are inversely associated with abdominal aortic calcification in men with type 2 diabetes mellitus. <i>Osteoporosis International</i> , 2013, 24, 2223-2230.	3.1	31
80	Undercarboxylated osteocalcin is positively associated with free testosterone in male patients with type 2 diabetes mellitus. <i>Osteoporosis International</i> , 2013, 24, 1115-1119.	3.1	45
81	Diagnostic criteria for primary osteoporosis: year 2012 revision. <i>Journal of Bone and Mineral Metabolism</i> , 2013, 31, 247-257.	2.7	251
82	Vertebral fracture risk after once-weekly teriparatide injections: follow-up study of Teriparatide Once-Weekly Efficacy Research (TOWER) trial. <i>Current Medical Research and Opinion</i> , 2013, 29, 195-203.	1.9	22
83	Effects of a single injection of teriparatide on bone turnover markers in postmenopausal women. <i>Osteoporosis International</i> , 2013, 24, 219-226.	3.1	38
84	Advanced glycation end products suppress osteoblastic differentiation of stromal cells by activating endoplasmic reticulum stress. <i>Biochemical and Biophysical Research Communications</i> , 2013, 438, 463-467.	2.1	37
85	Advanced glycation end products-induced reactive oxygen species generation is partly through NF-kappa B activation in human aortic endothelial cells. <i>Journal of Diabetes and Its Complications</i> , 2013, 27, 11-15.	2.3	42
86	Elevated Sclerostin Levels Are Associated With Vertebral Fractures in Patients With Type 2 Diabetes Mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 4030-4037.	3.6	95
87	Advanced Glycation End Products-induced Vascular Calcification is Mediated by Oxidative Stress: Functional Roles of NAD(P)H-oxidase. <i>Hormone and Metabolic Research</i> , 2013, 45, 267-272.	1.5	39
88	Decreased PTH Levels Accompanied by Low Bone Formation Are Associated with Vertebral Fractures in Postmenopausal Women with Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 1277-1284.	3.6	96
89	Bone metabolism and fracture risk in type 2 diabetes mellitus. <i>BoneKEy Reports</i> , 2012, 1, 36.	2.7	15
90	Role of Osteoglycin in the Linkage between Muscle and Bone. <i>Journal of Biological Chemistry</i> , 2012, 287, 11616-11628.	3.4	104

#	ARTICLE	IF	CITATIONS
91	Randomized Teriparatide [Human Parathyroid Hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) Trial for Examining the Reduction in New Vertebral Fractures in Subjects with Primary Osteoporosis and High Fracture Risk. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 3097-3106.	3.6	220
92	FAM5C is a soluble osteoblast differentiation factor linking muscle to bone. <i>Biochemical and Biophysical Research Communications</i> , 2012, 418, 134-139.	2.1	37
93	Interaction of Tmem119 and the bone morphogenetic protein pathway in the commitment of myoblastic into osteoblastic cells. <i>Bone</i> , 2012, 51, 158-167.	2.9	35
94	Japanese 2011 guidelines for prevention and treatment of osteoporosis—executive summary. <i>Archives of Osteoporosis</i> , 2012, 7, 3-20.	2.4	284
95	Advanced Glycation End Products (AGEs), but not High Glucose, Inhibit the Osteoblastic Differentiation of Mouse Stromal ST2 Cells Through the Suppression of Osterix Expression, and Inhibit Cell Growth and Increasing Cell Apoptosis. <i>Calcified Tissue International</i> , 2012, 91, 286-296.	3.1	83
96	Dose-response study of denosumab on bone mineral density and bone turnover markers in Japanese postmenopausal women with osteoporosis. <i>Osteoporosis International</i> , 2012, 23, 1131-1140.	3.1	48
97	Effects of intensive glycemic control on serum levels of insulin-like growth factor-I and dehydroepiandrosterone sulfate in Type 2 diabetes mellitus. <i>Journal of Endocrinological Investigation</i> , 2012, 35, 469-72.	3.3	11
98	Relationship between bone biochemical markers versus glucose/lipid metabolism and atherosclerosis; a longitudinal study in type 2 diabetes mellitus. <i>Diabetes Research and Clinical Practice</i> , 2011, 92, 393-399.	2.8	37
99	Serum insulin-like growth factor-I is negatively associated with serum adiponectin in type 2 diabetes mellitus. <i>Growth Hormone and IGF Research</i> , 2011, 21, 268-271.	1.1	20
100	Serum osteocalcin level is positively associated with insulin sensitivity and secretion in patients with type 2 diabetes. <i>Bone</i> , 2011, 48, 720-725.	2.9	117
101	Bone metabolism and fracture risk in type 2 diabetes mellitus [Review]. <i>Endocrine Journal</i> , 2011, 58, 613-624.	1.6	65
102	Serum undercarboxylated osteocalcin was inversely associated with plasma glucose level and fat mass in type 2 diabetes mellitus. <i>Osteoporosis International</i> , 2011, 22, 187-194.	3.1	223
103	Serum insulin-like growth factor-I is a marker for assessing the severity of vertebral fractures in postmenopausal women with type 2 diabetes mellitus. <i>Osteoporosis International</i> , 2011, 22, 1191-1198.	3.1	63
104	Effects of Metformin and Pioglitazone on Serum Pentosidine Levels in Type 2 Diabetes Mellitus. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2011, 119, 362-365.	1.2	35
105	Parathyroid Hormone-responsive Smad3-related Factor, Tmem119, Promotes Osteoblast Differentiation and Interacts with the Bone Morphogenetic Protein-Runx2 Pathway. <i>Journal of Biological Chemistry</i> , 2011, 286, 9787-9796.	3.4	71
106	Fasudil hydrochloride induces osteoblastic differentiation of stromal cell lines, C3H10T1/2 and ST2, via bone morphogenetic protein-2 expression. <i>Endocrine Journal</i> , 2010, 57, 415-421.	1.6	13
107	Effects of Treatment With Risedronate and Alfacalcidol on Progression of Atherosclerosis in Postmenopausal Women With Type 2 Diabetes Mellitus Accompanied With Osteoporosis. <i>American Journal of the Medical Sciences</i> , 2010, 339, 519-524.	1.1	23
108	Urinary deoxypyridinoline is a BMD-independent marker for prevalent vertebral fractures in postmenopausal women treated with glucocorticoid. <i>Osteoporosis International</i> , 2010, 21, 1585-1590.	3.1	11

#	ARTICLE	IF	CITATIONS
109	Baseline atherosclerosis parameter could assess the risk of bone loss during pioglitazone treatment in type 2 diabetes mellitus. <i>Osteoporosis International</i> , 2010, 21, 2013-2018.	3.1	35
110	Relationship between treatments with insulin and oral hypoglycemic agents versus the presence of vertebral fractures in type 2 diabetes mellitus. <i>Journal of Bone and Mineral Metabolism</i> , 2010, 28, 554-560.	2.7	88
111	Baseline serum total adiponectin level is positively associated with changes in bone mineral density after 1-year treatment of type 2 diabetes mellitus. <i>Metabolism: Clinical and Experimental</i> , 2010, 59, 1252-1256.	3.4	27
112	Relationships between dimethylarginine and the presence of vertebral fractures in type 2 diabetes mellitus. <i>Clinical Endocrinology</i> , 2010, 73, 463-468.	2.4	7
113	Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study: 12-Month, randomized, placebo-controlled, double-blind and 12-month open-label phases. <i>Bone</i> , 2010, 47, 493-502.	2.9	133
114	Low Serum Level of the Endogenous Secretory Receptor for Advanced Glycation End Products (esRAGE) Is a Risk Factor for Prevalent Vertebral Fractures Independent of Bone Mineral Density in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2009, 32, 2263-2268.	8.6	85
115	Adiponectin Is Associated with Changes in Bone Markers during Glycemic Control in Type 2 Diabetes Mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 3031-3037.	3.6	80
116	Activation of AMP kinase and inhibition of Rho kinase induce the mineralization of osteoblastic MC3T3-E1 cells through endothelial NOS and BMP-2 expression. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2009, 296, E139-E146.	3.5	82
117	Serum Osteocalcin Level Is Associated with Glucose Metabolism and Atherosclerosis Parameters in Type 2 Diabetes Mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 45-49.	3.6	381
118	Relationships between serum adiponectin levels versus bone mineral density, bone metabolic markers, and vertebral fractures in type 2 diabetes mellitus. <i>European Journal of Endocrinology</i> , 2009, 160, 265-273.	3.7	92
119	Analysis of factors affecting increase in bone mineral density at lumbar spine by bisphosphonate treatment in postmenopausal osteoporosis. <i>Journal of Bone and Mineral Metabolism</i> , 2009, 27, 76-82.	2.7	20
120	Serum Osteocalcin/Bone-Specific Alkaline Phosphatase Ratio Is a Predictor for the Presence of Vertebral Fractures in Men with Type 2 Diabetes. <i>Calcified Tissue International</i> , 2009, 85, 228-234.	3.1	52
121	Bone fragility in male glucocorticoid-induced osteoporosis is not defined by bone mineral density. <i>Osteoporosis International</i> , 2009, 20, 1889-1894.	3.1	30
122	Diabetic Patients Have an Increased Risk of Vertebral Fractures Independent of BMD or Diabetic Complications. <i>Journal of Bone and Mineral Research</i> , 2009, 24, 702-709.	2.8	274
123	Associations between components of the metabolic syndrome versus bone mineral density and vertebral fractures in patients with type 2 diabetes. <i>Bone</i> , 2009, 45, 174-179.	2.9	124
124	Rosuvastatin Increased Serum Osteocalcin Levels Independent of Its Serum Cholesterol-Lowering Effect in Patients with Type 2 Diabetes and Hypercholesterolemia. <i>Internal Medicine</i> , 2009, 48, 1869-1873.	0.7	22
125	Combination of Obesity with Hyperglycemia is a Risk Factor for the Presence of Vertebral Fractures in Type 2 Diabetic Men. <i>Calcified Tissue International</i> , 2008, 83, 324-331.	3.1	53
126	Metformin enhances the differentiation and mineralization of osteoblastic MC3T3-E1 cells via AMP kinase activation as well as eNOS and BMP-2 expression. <i>Biochemical and Biophysical Research Communications</i> , 2008, 375, 414-419.	2.1	188

#	ARTICLE	IF	CITATIONS
127	Serum intact parathyroid hormone levels predict hospitalisation for heart failure. <i>Heart</i> , 2008, 95, 395-398.	2.9	66
128	Serum Pentosidine Levels Are Positively Associated with the Presence of Vertebral Fractures in Postmenopausal Women with Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 1013-1019.	3.6	234
129	Serum DHEA-S Level Is Associated with the Presence of Atherosclerosis in Postmenopausal Women with Type 2 Diabetes Mellitus. <i>Endocrine Journal</i> , 2008, 55, 667-675.	1.6	28
130	The Combination of High Glucose and Advanced Glycation End-products (AGEs) Inhibits the Mineralization of Osteoblastic MC3T3-E1 Cells through Glucose-induced Increase in the Receptor for AGEs. <i>Hormone and Metabolic Research</i> , 2007, 39, 871-875.	1.5	121
131	The uraemic toxin phenylacetic acid inhibits osteoblastic proliferation and differentiation: an implication for the pathogenesis of low turnover bone in chronic renal failure. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 3160-3165.	0.7	30
132	Adiponectin and AMP kinase activator stimulate proliferation, differentiation, and mineralization of osteoblastic MC3T3-E1 cells. <i>BMC Cell Biology</i> , 2007, 8, 51.	3.0	155
133	Bone Mineral Density Is not Sensitive Enough to Assess the Risk of Vertebral Fractures in Type 2 Diabetic Women. <i>Calcified Tissue International</i> , 2007, 80, 353-358.	3.1	49
134	Serum insulin-like growth factor-I level is associated with the presence of vertebral fractures in postmenopausal women with type 2 diabetes mellitus. <i>Osteoporosis International</i> , 2007, 18, 1675-1681.	3.1	54
135	The Threshold of Bone Mineral Density for Vertebral Fracture in Female Patients with Glucocorticoid-induced Osteoporosis. <i>Endocrine Journal</i> , 2006, 53, 27-34.	1.6	49
136	Body composition and vertebral fracture risk in female patients treated with glucocorticoid. <i>Osteoporosis International</i> , 2006, 17, 627-633.	3.1	21
137	Serum Levels of Insulin-Like Growth Factor (IGF); IGF-Binding Proteins-3, -4, and -5; and Their Relationships to Bone Mineral Density and the Risk of Vertebral Fractures in Postmenopausal Women. <i>Calcified Tissue International</i> , 2006, 78, 18-24.	3.1	64
138	Parathyroid Hormone Increases $\beta$ -Catenin Levels through Smad3 in Mouse Osteoblastic Cells. <i>Endocrinology</i> , 2006, 147, 2583-2590.	2.8	115
139	The Usefulness of Bone Metabolic Indices for the Prediction of Changes in Bone Mineral Density after Parathyroidectomy in Patients with Primary Hyperparathyroidism. <i>Hormone and Metabolic Research</i> , 2006, 38, 411-416.	1.5	20
140	Menin Is Required for Bone Morphogenetic Protein 2- and Transforming Growth Factor $\beta$ -regulated Osteoblastic Differentiation through Interaction with Smads and Runx2. <i>Journal of Biological Chemistry</i> , 2004, 279, 40267-40275.	3.4	122
141	Inactivation of Menin, the Product of the Multiple Endocrine Neoplasia Type 1 Gene, Inhibits the Commitment of Multipotential Mesenchymal Stem Cells into the Osteoblast Lineage. <i>Journal of Biological Chemistry</i> , 2003, 278, 21058-21069.	3.4	79
142	Activations of ERK1/2 and JNK by Transforming Growth Factor $\beta$ Negatively Regulate Smad3-induced Alkaline Phosphatase Activity and Mineralization in Mouse Osteoblastic Cells. <i>Journal of Biological Chemistry</i> , 2002, 277, 36024-36031.	3.4	110
143	Posttranscriptional Control of Adipocyte Differentiation through Activation of Phosphoinositide 3-Kinase. <i>Journal of Biological Chemistry</i> , 1998, 273, 28945-28952.	3.4	136
144	Serum Levels of Insulin-like Growth Factor (IGF) I, IGF-Binding Protein (IGFBP)-2, and IGFBP-3 in Osteoporotic Patients with and without Spinal Fractures. <i>Journal of Bone and Mineral Research</i> , 1997, 12, 1272-1279.	2.8	167

#	ARTICLE	IF	CITATIONS
145	Hemangiopericytoma-Like Intranasal Tumor: A Case Report with an Immunohistochemical Study. <i>Otolaryngology - Head and Neck Surgery</i> , 1995, 113, 323-327.	1.9	8
146	Femoral and spinal bone mineral density in Japanese osteoporotics with hip fracture. <i>Osteoporosis International</i> , 1994, 4, 144-148.	3.1	22
147	Ki-ras and c-myc Oncogene Expression Measured by Coamplification Polymerase Chain Reaction. <i>Biochemical and Biophysical Research Communications</i> , 1994, 201, 574-580.	2.1	10
148	Malignant oncocytoma of the parotid gland: a case report with an immunohistochemical and ultrastructural study. <i>Journal of Laryngology and Otology</i> , 1993, 107, 69-74.	0.8	37
149	Comparison of bone mineral content among Japanese, Koreans, and Taiwanese assessed by dual-photon absorptiometry. <i>Journal of Bone and Mineral Research</i> , 1992, 7, 153-159.	2.8	57
150	Effects of high concentrations of glucose on PTH secretion in parathyroid cells. <i>Kidney International</i> , 1990, 37, 1522-1527.	5.2	104
151	Nasopharyngeal Carcinomas and Malignant Lymphomas. <i>Laryngoscope</i> , 1990, 100, 742-748.	2.0	5
152	Evaluation of antifibrillatory effects of drugs. <i>American Journal of Cardiology</i> , 1989, 64, J33-J36.	1.6	5
153	Calcitonin gene-related peptide-like immunoreactivity in neuronal elements of the cat cerebellum. <i>Brain Research</i> , 1988, 439, 147-154.	2.2	23
154	Quinolinic and kainic acids can enhance calcitonin gene-related peptide-like immunoreactivity in striatal neurons with substance P-like immunoreactivity. <i>Brain Research</i> , 1987, 418, 392-397.	2.2	10
155	Changes of neurotensinlike immunoreactivity in the striatum of the cat after intrastriatal injection of kainic acid. <i>Journal of Comparative Neurology</i> , 1987, 263, 607-612.	1.6	6